Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1970 Jun;1(6):559–565. doi: 10.1128/iai.1.6.559-565.1970

Protective Effect of Vaccines in Experimental Mycoplasma pneumoniae Disease

Gerald W Fernald 1, Wallace A Clyde Jr 1
PMCID: PMC415942  PMID: 16557776

Abstract

The mechanisms of immunity to Mycoplasma pneumoniae were investigated by evaluating different vaccination procedures in an experimental animal model. Hamsters were immunized by intranasal inoculation of broth cultures or by parenteral injections of saline-suspended organisms. All vaccinees received a standardized intranasal challenge which produced pneumonia in 94% of controls. Intranasal immunization with virulent organisms produced a 71% reduction in pneumonia. Subcutaneous and intraperitoneal inoculation of the same organisms yielded 56 and 61% reductions, respectively. Animals similarly immunized with an attenuated strain developed resistance to pneumonia only after intranasal infection. Serum antibody levels did not correlate with protection. Growth-inhibiting activity was demonstrated in bronchial washings of challenged animals, suggesting the development of local antibody in response to infection with M. pneumoniae. Crosschallenge studies were performed in animals vaccinated intranasally with virulent and avirulent variants of the same strain. The avirulent vaccine prevented pneumonia in animals challenged with homologous virulent organisms but not in those receiving an unrelated strain; the virulent vaccine provided protection to both homologous and heterologous challenge. These studies indicate that organism strain variation as well as vaccination technique are important determinants of the immune response to M. pneumoniae.

Full text

PDF
559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. COUCH R. B., CATE T. R., CHANOCK R. M. INFECTION WITH ARTIFICIALLY PROPAGATED EATON AGENT (MYCOPLASMA PNEUMONIAE). IMPLICATIONS FOR DEVELOPMENT OF ATTENUATED VACCINE FOR COLD AGGLUTININ-POSITIVE PNEUMONIA. JAMA. 1964 Feb 8;187:442–447. [PubMed] [Google Scholar]
  2. DAJANI A. S., CLYDE W. A., Jr, DENNY F. W. EXPERIMENTAL INFECTION WITH MYCOPLASMA PNEUMONIAE (EATON'S AGENT). J Exp Med. 1965 Jun 1;121:1071–1086. doi: 10.1084/jem.121.6.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies G. The examination of nasal mucus for antibodies to mycoplasma mycoides. Vet Rec. 1969 Apr 19;84(16):417–418. doi: 10.1136/vr.84.16.417. [DOI] [PubMed] [Google Scholar]
  4. Fernald G. W., Clyde W. A., Jr, Denny F. W. Factors influencing growth inhibition of Mycoplasma pneumoniae by immune sera. Proc Soc Exp Biol Med. 1967 Oct;126(1):161–166. doi: 10.3181/00379727-126-32391. [DOI] [PubMed] [Google Scholar]
  5. Fernald G. W., Clyde W. A., Jr, Denny F. W. Nature of the immune response to Mycoplasma pneumoniae. J Immunol. 1967 May;98(5):1028–1038. [PubMed] [Google Scholar]
  6. Fernald G. W. Immunologic aspects of experimental Mycoplasma pneumoniae infection. J Infect Dis. 1969 Mar;119(3):255–266. doi: 10.1093/infdis/119.3.255. [DOI] [PubMed] [Google Scholar]
  7. Jensen K. E., Senterfit L. B., Chanock R. M., Smith C. B., Purcell R. H. An inactivated mycoplasma pneumoniae vaccine. JAMA. 1965 Oct 18;194(3):248–252. [PubMed] [Google Scholar]
  8. Lipman R. P., Clyde W. A., Jr The interrelationship of virulence, cytadsorption, and peroxide formation in Mycoplasma pneumoniae. Proc Soc Exp Biol Med. 1969 Sep;131(4):1163–1167. doi: 10.3181/00379727-131-34061. [DOI] [PubMed] [Google Scholar]
  9. Metzgar D. P., Woodhour A. F., Vella P. P., Weibel R. E., Stokes J., Jr, Drake M. E., Tytell A. A., Hilleman M. R. Respiratory virus vaccines. II. Mycoplasma pneumoniae (Eaton agent) vaccines. Am Rev Respir Dis. 1966 Jul;94(1):1–9. doi: 10.1164/arrd.1966.94.1.1. [DOI] [PubMed] [Google Scholar]
  10. Mogabgab W. J. Protective effects of inactive Mycoplasma pneumoniae vaccine in military personnel, 1964-1966. Am Rev Respir Dis. 1968 Mar;97(3):359–365. doi: 10.1164/arrd.1968.97.3.359. [DOI] [PubMed] [Google Scholar]
  11. Smith C. B., Chanock R. M., Friedewald W. T., Alford R. H. Mycoplasma pneumoniae infections in volunteers. Ann N Y Acad Sci. 1967 Jul 28;143(1):471–483. doi: 10.1111/j.1749-6632.1967.tb27691.x. [DOI] [PubMed] [Google Scholar]
  12. Smith C. B., Friedewald W. T., Chanock R. M. Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. JAMA. 1967 Feb 6;199(6):353–358. [PubMed] [Google Scholar]
  13. Steinberg P., White R. J., Fuld S. L., Gutekunst R. R., Chanock R. M., Senterfit L. B. Ecology of Mycoplasma pneumoniae infections in marine recruits at Parris Island, South Carolina. Am J Epidemiol. 1969 Jan;89(1):62–73. doi: 10.1093/oxfordjournals.aje.a120916. [DOI] [PubMed] [Google Scholar]
  14. Waldman R. H., Mann J. J., Kasel J. A. Influenza virus neutralizing antibody in human respiratory secretions. J Immunol. 1968 Jan;100(1):80–85. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES